Compare
Co-Diagnostics, Inc. vs Catheter Precision, Inc. vs Sintx Technologies, Inc. vs Pulse Biosciences, Inc.
| Latest fiscal year | Co-Diagnostics, Inc. CODX | Catheter Precision, Inc. VTAK | Sintx Technologies, Inc. SINT | Pulse Biosciences, Inc. PLSE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $622.5K | $819.0K | $1.02M | $350.0K |
| Revenue growth (YoY) | -84.1% | +95.0% | -64.7% | n/a |
| Gross margin | 64.3% | 92.3% | 45.3% | -54.0% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$46.90M | -$17.18M | -$10.36M | -$72.78M |
| EPS (Diluted) | -$35.25 | n/a | -$6.16 | n/a |
| Operating cash flow | -$29.14M | -$8.30M | -$8.57M | -$54.12M |
| Free cash flow | -$29.84M | -$8.31M | -$8.76M | -$54.44M |
| Cash & equivalents | $11.88M | $88.0K | $4.14M | $80.73M |
| Total assets | $24.74M | $15.86M | $9.51M | $94.54M |
| Total liabilities | $4.11M | $9.21M | $6.58M | $13.88M |
| Shareholders' equity | $20.63M | $7.05M | $2.93M | $80.66M |
| Return on year-end equity | -227.3% | -243.6% | -353.8% | -90.2% |
| Shares outstanding | 2.10M | 1.74M | 3.97M | 67.84M |
Revenue, most recent five fiscal years
| Fiscal year | Co-Diagnostics, Inc. | Catheter Precision, Inc. | Sintx Technologies, Inc. | Pulse Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $622.5K Ended 2025-12-31 | $819.0K Ended 2025-12-31 | $1.02M Ended 2025-12-31 | $350.0K Ended 2025-12-31 |
| 1 year earlier | $3.92M Ended 2024-12-31 | $420.0K Ended 2024-12-31 | $2.89M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $6.81M Ended 2023-12-31 | $442.0K Ended 2023-12-31 | $2.63M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $34.22M Ended 2022-12-31 | $14.0K Ended 2022-12-31 | $1.56M Ended 2022-12-31 | $700.0K Ended 2022-12-31 |
| 4 years earlier | $97.89M Ended 2021-12-31 | $22.0K Ended 2021-12-31 | $606.0K Ended 2021-12-31 | $1.42M Ended 2021-12-31 |